Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
ProJenX ALS drug gets back on the map after partial FDA hold
ProJenX is back on the map after the FDA lifted a partial clinical hold on a phase 1 clinical trial for an amyotrophic lateral sclerosis drug.
Annalee Armstrong
Mar 29, 2024 10:44am
Headlands acquires Pharmasite to expand mental health trials
Feb 29, 2024 4:20pm
Alto Neuroscience preps IPO to push CNS therapies through clinic
Jan 16, 2024 6:51am
Daiichi taps Confo to hit once-undruggable target in $182M deal
Mar 30, 2023 5:00am
Gossamer pauses CNS med enrollment, citing risk-benefit profile
Mar 17, 2023 11:16am
Neurocrine blows fresh wind in Voyager's sails with $175M payday
Jan 9, 2023 9:30am